The Kent-based company has employed John Lyttle to develop the strategic services offered to its clients. He will head up Wells’ London office, which is due to open in 2008. He reports to Wells MD Mark Forbes Irving.
Lyttle was previously global new products director at the Chiron business unit of Novartis Vaccines and Diagnostics, which he left in 2006. Since leaving Novartis he has consulted blue-chip companies.
Before joining Novartis, Lyttle worked at Powderject Pharmaceuticals and Wyeth Lederle.
